FDA approves first digital ingestion tracking system med

Wednesday, 15 November 2017, 12:11:15 AM. The Food and Drug Administration has approved the first drug in the United States with a digital ingestion tracking system, in an unprecedented move to ensure that patients with mental illness take…
WASHINGTON — The Food and Drug Administration has approved the first drug in the United States with a digital ingestion tracking system, in an unprecedented move to ensure that patients with mental illness take the medicine prescribed for them. The drug Abilify MyCite was developed by Otsuka Pharmaceutical Co., Ltd. The drug Abilify was first approved by the FDA in 2002 to treat schizophrenia, and the ingestible sensor, made by Proteus Digital health, was approved for marketing in 2012. The FDA said in a statement Monday that the digitally enhanced medication “works by sending a message from the pill’s sensor to a wearable patch.” “Being able to track ingestion of medications prescribed for illness may be useful for some patients,” said Dr. Mitchell Mathis, director of the division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research. “The FDA supports the development and use of new technology in prescription drugs and is committed to working with companies to understand how this technology might benefit patients and prescribers.” Green-lighting the new medication, however, came with some caveats. Among them, the FDA said it was important to note that Abilify MyCite’s labeling asserts “the ability of the product to improve patient compliance with their treatment regimen has not been shown.” “Abilify MyCite should not be used to track drug ingestion in ‘real-time’ or during an emergency,” the statement said, “because detection may be delayed or may not...Read more
Share this

You might also like

Similar